NCT06079736Phase 2Terminated

A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-08-28Actual

Enrollment · participants7Actual

Source updated2025-12-02Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-10-01 · 3 fields changed

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~Apr 2025~~

+ After

28 Aug 2025

Recruitment status changed

− Before

~~Active not recruiting~~

+ After

Terminated

Check registry source

Study details

Conditions studied

Duchenne Muscular Dystrophy

Treatments or interventions studied

PGN-EDO51Drug

Primary outcomes · main study measures

measure: Adverse events and serious adverse events (safety and tolerability of PGN-EDO51 in MAD period); description: Adverse events and serious adverse events; timeFrame: Baseline to Week 16; measure: Adverse events and serious adverse events (long-term safety and tolerability of PGN-EDO51 in LTE period); description: Adverse events and serious adverse events; timeFrame: Baseline to Week 108

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history